Hybrigenics receives positive opinion for European patent on high therapeutic doses of inecalcitol
Filed in 2009, the patent will cover inecalcitol doses higher than one milligram (mg) per day until 2029. Currently-marketed vitamin D analogues for indications such as rickets, osteoporosis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.